Japan Reimburses E Keppra For Status Epilepticus After Physician Push
Executive Summary
Following an investigator-initiated clinical development program demonstrating its value, Japan has granted reimbursement to UCB's anticonvulsant E Keppra for status epilepticus, pending what appears to be the formal approval globally in this indication.
You may also be interested in...
Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite
The Japanese government will apply new drug reimbursement prices from 1 April, under which Pfizer’s Vyndaqel will be slashed by 75% and UCB's E Keppra by 26%. Nobelpharma and Santen will be also affected by the revision, which averages close to 7% across the board.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Otsuka Progresses Digital Push With US Approval Of MDD App
Otsuka/Click’s global-first adjunctive digital therapy for depression marks another step by pharmaceutical firms going digital for psychotherapy through collaborations.